AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cu concentrations in patients with infectious diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cu levels in patients with renal diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cu levels in patients with infectious diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cu levels in patients with GI & hepatic diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Zn concentrations in patients with GI & hepatic diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Zn concentrations in patients with infectious diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Zn concentrations in patients with renal diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Zn concentrations in patients with cardiovascular diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Zn concentrations in patients with malignant diseases
Number of subjects: 118
Study 10511772 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Cu/Zn ratios in patients with cancer and other diseases
Number of subjects: 118
Study 8537416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure garment therapy
Number of subjects: 122
Study 8537416 — intervention group
Group type: COMPARATOR
Intervention: No pressure garment therapy
Number of subjects: 122
Study 2197046 — intervention group
Group type: EXPERIMENTAL
Intervention: TP‐1 (Serono; 1 mg/kg body weight) administered by daily i.m. injections for the first 14 days followed by two injections/week for 6 further weeks
Number of subjects: 20
Study 2197046 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 6363099 — intervention group
Group type: EXPERIMENTAL
Intervention: porcine Actrapid + Lente MC
Number of subjects: 26
Study 6363099 — intervention group
Group type: COMPARATOR
Intervention: Regular + NPH‐Biosynthetic human insulin
Number of subjects: 26
Study 6363099 — intervention group
Group type: EXPERIMENTAL
Intervention: porcine Actrapid + Monotard
Number of subjects: 26
Study 6363099 — intervention group
Group type: EXPERIMENTAL
Intervention: Actrapid + Monotard‐Semisynthetic human insulin
Number of subjects: 26
Study 31539077 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 and ATM comutation
Number of subjects: 2020
Study 29505000 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hepatic duct orifice (LHD) group, n = 35
Number of subjects: 62
Study 29505000 — intervention group
Group type: COMPARATOR
Intervention: Common bile duct (CBD) group, n = 27
Number of subjects: 62
Study 27713892 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (6 education sessions and follow-up by phone call)
Number of subjects: 60
Study 27713892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 24469620 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR) under local anaesthesia
Number of subjects: 558
Study 24469620 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 558
Study 24469620 — intervention group
Group type: COMPARATOR
Intervention: Patients randomized outside routine working hours
Number of subjects: 558
Study 24469620 — intervention group
Group type: COMPARATOR
Intervention: Lowest systolic blood pressure below 70 mmHg
Number of subjects: 558
Study 23249818 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study 23249818 — intervention group
Group type: COMPARATOR
Intervention: Light exercise
Number of subjects: 20
Study 20939917 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (8 sessions)
Number of subjects: 109
Study 20939917 — intervention group
Group type: COMPARATOR
Intervention: General practitioner's care according to The Dutch College of General Practitioners Practice Guideline (NHG-standard)
Number of subjects: 109
Study 18086795 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole + triptorelin (+/‐ zoledronate)
Number of subjects: 81
Study 18086795 — intervention group
Group type: COMPARATOR
Intervention: tamoxifen + triptorelin
Number of subjects: 81
Study 15986783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 89
Study 12511175 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980
Study 12511175 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study 8688263 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP) at an initial rate of 1‐2 micrograms kg‐1 min‐1
Number of subjects: 60
Study 8688263 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil with bolus injections of 25 mg and an i.v. infusion at an initial rate of 11‐21 micrograms kg‐1 min‐1
Number of subjects: 60
Study 1907206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutromat
Number of subjects: 30
Study 1907206 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexiflo
Number of subjects: 30
Study 1907206 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenta
Number of subjects: 30
Study 7038945 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 milligram epidurally administered morphine sulfate
Number of subjects: 30
Study 7038945 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 milligram epidurally injected morphine sulfate
Number of subjects: 30
Study 7038945 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study 30885375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 1120
Study 30885375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120
Study 30486789 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity of chest pain (≥4 on the visual analogue scale)
Number of subjects: 1603
Study 27111221 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA from the tumor of AA CRC patients
Number of subjects: 0
Study 27111221 — intervention group
Group type: COMPARATOR
Intervention: DNA from the tumor of CA CRC patients
Number of subjects: 0
Study 27111221 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA sequencing analysis in AA patients with CRC
Number of subjects: 0
Study 25190523 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 1663
Study 25190523 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1663
Study 25190523 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 1663
Study 21219121 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure device (Omron HEM‐705CP)
Number of subjects: 220
Study 21219121 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometry
Number of subjects: 220
Study 21219121 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 220
Study 20648004 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent colonoscopy (≤ 12 h)
Number of subjects: 72
Study 20648004 — intervention group
Group type: COMPARATOR
Intervention: Elective colonoscopy (36‐60 h after presentation)
Number of subjects: 72
Study 17445637 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (10 g)
Number of subjects: 167
Study 17445637 — intervention group
Group type: COMPARATOR
Intervention: DMSO with lidocaine (10 g of 40% DMSO)
Number of subjects: 167
Study 15127090 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg twice daily)
Number of subjects: 34
Study 15127090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11772908 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg once daily
Number of subjects: 18
Study 11772908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9848840 — intervention group
Group type: EXPERIMENTAL
Intervention: High stimulation of vagus nerve
Number of subjects: 18
Study 9848840 — intervention group
Group type: COMPARATOR
Intervention: Low stimulation of vagus nerve
Number of subjects: 18
Study 7867437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPLX)
Number of subjects: 200
Study 7867437 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (OFLX)
Number of subjects: 200
Study 2769581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) mean daily intake of 2.44 grams
Number of subjects: 23
Study 2769581 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) mean daily intake of 1.29 grams
Number of subjects: 23
Study 2769581 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy persons similar in age, taking no medication)
Number of subjects: 23
Study 30101 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4.0 mg intravenous injection)
Number of subjects: 20
Study 30101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31903699 — intervention group
Group type: COMPARATOR
Intervention: Bayesian augmented control (BAC) trial design for glioblastoma study; informative prior used for control arm hazard rate.
Number of subjects: 0
Study 31903699 — intervention group
Group type: COMPARATOR
Intervention: Bayesian augmented control (BAC) trial design for pancreatic cancer study; hierarchical model borrowing method used.
Number of subjects: 0
Study 30501396 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific goal intervention (n=25)
Number of subjects: 50
Study 30501396 — intervention group
Group type: COMPARATOR
Intervention: Standardized intervention (n=25)
Number of subjects: 50
Study 29105594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1370
Study 29105594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1370
Study 25373834 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training and use of a patient booklet
Number of subjects: 66
Study 25373834 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care test
Number of subjects: 66
Study 23929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide
Number of subjects: 76
Study 23929932 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 76
Study 23929932 — intervention group
Group type: COMPARATOR
Intervention: Comparison between valsartan/hydrochlorothiazide and amlodipine
Number of subjects: 76
Study 21944620 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural checklist with basic team training
Number of subjects: 10
Study 21944620 — intervention group
Group type: COMPARATOR
Intervention: Standard laparoscopic cholecystectomies
Number of subjects: 10
Study 19254854 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (valproate)
Number of subjects: 549
Study 16311026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary support for weight gain in underweight patients
Number of subjects: 71
Study 14668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux administered at a subcutaneous dose of 2.5 mg qd, starting postoperatively
Number of subjects: 0
Study 14668420 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux administered for 4 weeks after hip fracture surgery
Number of subjects: 0
Study 14668420 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 10% sodium thiopental
Number of subjects: 146
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 20% sodium thiopental
Number of subjects: 146
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 30% sodium thiopental
Number of subjects: 146
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 40% sodium thiopental
Number of subjects: 146
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 50% sodium thiopental
Number of subjects: 146
Study 11000658 — intervention group
Group type: COMPARATOR
Intervention: Pure propofol
Number of subjects: 146
Study 11000658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure sodium thiopental
Number of subjects: 146
Study 8630624 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (20,000 u/ml)
Number of subjects: 9
Study 8630624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg)
Number of subjects: 9
Study 8630624 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 9
Study 8630624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1448789 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 grams of n‐3 PUFA
Number of subjects: 40
Study 1448789 — intervention group
Group type: COMPARATOR
Intervention: 20 grams of n‐6 PUFA
Number of subjects: 40
Study 2417477 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (oral, 8 to 22 micrograms/ml serum concentration)
Number of subjects: 10
Study 29584539 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme led by nurses over 12 months (pre-test, 6 months of intervention, 12 months of intervention, and 1-year follow-up post-intervention)
Number of subjects: 74
Study 29584539 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme led by nurses
Number of subjects: 74
Study 29584539 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 74
Study 27109947 — intervention group
Group type: EXPERIMENTAL
Intervention: Late introduction of Everolimus (EVR) with tacrolimus reduction in group A (n=24)
Number of subjects: 49
Study 27109947 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive regimen in group B (n=25)
Number of subjects: 49
Study 27109947 — intervention group
Group type: EXPERIMENTAL
Intervention: Late introduction of Everolimus (EVR) in group A
Number of subjects: 49
Study 27109947 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive regimen in group B
Number of subjects: 49
Study 24748001 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-exposed group (1.5 T magnetic flux density, conventional brain MRI, 15 min, 99 slices)
Number of subjects: 16
Study 24748001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MRI exposure)
Number of subjects: 16
Study 24748001 — intervention group
Group type: COMPARATOR
Intervention: Comparison of urinary mercury levels between groups at 72 hrs after MRI
Number of subjects: 16
Study 22873531 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tofacitinib twice daily
Number of subjects: 717
Study 22873531 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tofacitinib twice daily
Number of subjects: 717
Study 22873531 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg adalimumab once every 2 weeks
Number of subjects: 717
Study 22873531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 22873531 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg or 10 mg tofacitinib
Number of subjects: 717
Study 20367668 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% urea moisturizer
Number of subjects: 100
Study 20367668 — intervention group
Group type: COMPARATOR
Intervention: 10% urea lotion
Number of subjects: 100
Study 18583219 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (1 microg/mL naloxone and 1 mg/mL morphine)
Number of subjects: 120
Study 18583219 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (0 microg/mL naloxone and 1 mg/mL morphine)
Number of subjects: 120
Study 18583219 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study 15799919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (150 +/- 150 microg/kg) added to tepid blood cardioplegia
Number of subjects: 0
Study 15799919 — intervention group
Group type: COMPARATOR
Intervention: Control group (tepid blood cardioplegia without diltiazem)
Number of subjects: 0
Study 10770188 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of endurance exercise training
Number of subjects: 10
Study 9077048 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic techniques (audiotape with relaxation induction and posthypnotic suggestions)
Number of subjects: 69
Study 9077048 — intervention group
Group type: COMPARATOR
Intervention: No hypnotic techniques (control group)
Number of subjects: 69
Study 8366819 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated immunization schedule (group A): immunized at 4 days, 1 month, and 3 months of life with 10 micrograms of recombinant HBV vaccine (Engerix B, SKF)
Number of subjects: 504
Study 8366819 — intervention group
Group type: COMPARATOR
Intervention: Traditional immunization schedule (group B): immunized at 4 days, 1 month, and 6 months of life with 10 micrograms of recombinant HBV vaccine (Engerix B, SKF)
Number of subjects: 504
Study 3110662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 80
Study 3110662 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (Aza)
Number of subjects: 80
Study 3110662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) converted to Azathioprine (Aza)
Number of subjects: 80
Study 31631048 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 232
Study 31631048 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 232
Study 29678459 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in suburban schools
Number of subjects: 38078
Study 29678459 — intervention group
Group type: EXPERIMENTAL
Intervention: School-located influenza vaccination (SLIV) in urban schools
Number of subjects: 38078
Study 29678459 — intervention group
Group type: EXPERIMENTAL
Intervention: Second year of SLIV in urban schools
Number of subjects: 38078
Study 29678459 — intervention group
Group type: EXPERIMENTAL
Intervention: Second year of SLIV in suburban schools
Number of subjects: 38078
Study 27722752 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral implantation of FineVision trifocal IOL
Number of subjects: 23
Study 27722752 — intervention group
Group type: COMPARATOR
Intervention: Mix-and-match bifocal ReSTOR +2.50 and +3.00 D IOLs
Number of subjects: 23
Study 24967383 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging trainees by assessing peer performance during simulation-based training
Number of subjects: 84
Study 24967383 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer assessment)
Number of subjects: 84
Study 22143258 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-only contraceptive pills
Number of subjects: 0
Study 22143258 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal contraceptive pills
Number of subjects: 0
Study 22143258 — intervention group
Group type: COMPARATOR
Intervention: Progestin-only and Combined hormonal contraceptive pills
Number of subjects: 0
Study 20464321 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup A - F applied to enamel without an intermediate bonding agent layer
Number of subjects: 30
Study 20464321 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup B - SB applied, light-cured, then F applied and light-cured
Number of subjects: 30
Study 20464321 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup C - PB applied, light-cured, then F applied and light-cured
Number of subjects: 30
Study 18433918 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment after 6 weeks of pegylated interferon‐alpha2a/ribavirin therapy
Number of subjects: 74
Study 18433918 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment after 6 weeks of pegylated interferon‐alpha2a/ribavirin therapy
Number of subjects: 74
Study 15755826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling (and placebo capsules)
Number of subjects: 563
Study 15755826 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (no dietary counseling)
Number of subjects: 563
Study 15755826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling and n-3 PUFA supplementation
Number of subjects: 563
Study 15755826 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary counseling and placebo capsules)
Number of subjects: 563
Study 14650955 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) plus leucovorin (LV) therapy for 6 months after curative resection of Dukes' C CRC
Number of subjects: 0
Study 14650955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of UFT and LV
Number of subjects: 0
Study 14650955 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrahepatic arterial infusion (IHA) therapy
Number of subjects: 0
Study 14650955 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 as second-line therapy
Number of subjects: 0
Study 10368116 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial‐synchronous ventricular pacing (RV, LV, or both ventricles simultaneously) at preselected AV delays.
Number of subjects: 27
Study 8814706 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP (bleomycin, etoposide, cisplatin)
Number of subjects: 0
Study 8814706 — intervention group
Group type: COMPARATOR
Intervention: EP (etoposide, cisplatin)
Number of subjects: 0
Study 2005224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-containing drug delivery fibers (25% by weight tetracycline hydrochloride)
Number of subjects: 10
Study 2005224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tetracycline-containing fibers and scaling
Number of subjects: 10
Study 2005224 — intervention group
Group type: COMPARATOR
Intervention: Conventional scaling alone
Number of subjects: 10
Study 2005224 — intervention group
Group type: COMPARATOR
Intervention: Untreated sites
Number of subjects: 10
Study 6828530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (16 mg, 32 mg, 48 mg)
Number of subjects: 4
Study 6828530 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (16 mg, 32 mg, 48 mg)
Number of subjects: 4
Study 6828530 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 4
Study 31382934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection of the inferior mesenteric vein (IMV) towards the inferior mesenteric artery (IMA)
Number of subjects: 90